There have been major advances in new therapies, diagnostic tools, and strategies for treatment and prevention of fungal infections. Despite these encouraging developments, large numbers of patients are at risk for infectious diseases, and the epidemiology of invasive mycoses continues to emerge. The diagnosis of these infections remains difficult, and treatment outcomes in highly immunosuppressed patients remain poor. Thus, this issue is devoted to state-of-the-art updates on fungal infections by internationally recognized authorities in this field. Some topics covered are Antifungal agents; State-of-the-art culture, identification, and resistance testing of fungal pathogens; Non-culture diagnostics in fungal disease; Contemporary strategies in the prevention and management of fungal infections; Invasive candidiasis; Invasive aspergillosis; Mucormycoses; and Cryptococcosis to name a few.

Fungal Infections, An Issue of Infectious Disease Clinics of North America, E-Book

There have been major advances in new therapies, diagnostic tools, and strategies for treatment and prevention of fungal infections. Despite these encouraging developments, large numbers of patients are at risk for infectious diseases, and the epidemiology of invasive mycoses continues to emerge. The diagnosis of these infections remains difficult, and treatment outcomes in highly immunosuppressed patients remain poor. Thus, this issue is devoted to state-of-the-art updates on fungal infections by internationally recognized authorities in this field. Some topics covered are Antifungal agents; State-of-the-art culture, identification, and resistance testing of fungal pathogens; Non-culture diagnostics in fungal disease; Contemporary strategies in the prevention and management of fungal infections; Invasive candidiasis; Invasive aspergillosis; Mucormycoses; and Cryptococcosis to name a few.

A concise one-stop-practical reference for the various physicians dealing with fungal infections, Antifungal Therapy appeals to infectious disease physicians, transplant surgeons, dermatologists, and intensivists, as well as basic scientists and pharmaceutical company researchers interested in the state of antifungal therapy. This book provides a c

This book is open access under a CC BY license. The narrative of 20th-century medicine is the conquering of acute infectious diseases and the rise in chronic, degenerative diseases. The history of fungal infections does not fit this picture. This book charts the path of fungal infections from the mid 19th century to the dawn of the 21st century.

The traditional end-points for clinical studies of lung diseases were based on functional parameters. Their value as surrogate markers for disease activity and progression has been increasingly questioned by scientists, carers, regulatory agencies and funding bodies. Novel tools and methods with regard to biomarkers and patient-reported outcomes have made these parameters emerge from their status as interesting secondary end-points and become potential primary outcomes for clinical trials. Nevertheless, their relevance and validity still needs to be proven. This issue of the European Respiratory Monograph describes the current status regarding end-points in all relevant areas of pulmonary medicine.